Skip to main content

Table 1 Baseline transplantation characteristics

From: Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation

 

All (n = 32)

Group 1: Never cGvHD (n = 10)

Group 2: Resolved cGvHD (n = 11)

Group 3: Active cGvHD (n = 11)

p-value

Patient age at the time of transplantation, years

Median (IQR)

39 (26, 47)

42 (34, 49)

28 (21, 49)

40 (31, 48)

.199

Patient age at the time of survey, years

Median (IQR)

53 (37, 62)

59 (45, 63)

41 (29, 60)

54 (36, 62)

.264

Follow-up time, months

Median (IQR)

153 (113, 191)

174 (103, 231)

152 (113, 199)

151 (120, 182)

.623

Gender, n (%)

Women

13 (41.0%)

3 (30.0%)

5 (45.5%)

5 (45.5%)

.712

Men

19 (59.0%)

7 (70.0%)

6 (54.5%)

6 (54.5%)

Diagnosis, n (%)

Primary AML

22 (68.8%)

7 (70.0%)

7 (63.6%)

8 (72.7%)

.895

Secondary AML

10 (31.3%)

3 (30.0%)

4 (36.4%)

3 (27.3%)

2017 European LeukemiaNet genetic risk stratification, n (%)

Favorable

6 (18.8%)

2 (20.0%)

3 (27.3%)

1 (9.1%)

.829

Intermediate

18 (56.3%)

6 (60.0%)

5 (45.5%)

7 (63.6%)

Adverse

8 (25.0%)

2 (20.0%)

3 (27.3%)

3 (27.3%)

Remission status at the time of transplantation, n (%)

First complete remission (CR1)

15 (46.9%)

5 (50.0%)

4 (36.4%)

6 (54.5%)

.700

First partial remission (PR1), CR2

12 (37.5%)

3 (30.0%)

6 (54.5%)

3 (27.3%)

 > CR2, primary refractory AML

5 (15.6%)

2 (20.0%)

1 (9.1%)

2 (18.2%)

Hematopoietic stem cell transplantation comorbidity index (HCT-CI), n (%)

0

16 (50.0%)

6 (60.0%)

4 (36.4%)

6 (54.5%)

.712

1–2

11 (34.4%)

2 (20.0%)

5 (45.5%)

4 (36.4%)

 ≥ 3

5 (15.6%)

2 (20.0%)

2 (18.2%)

1 (9.1%)

Karnofsky performance score, n (%)

 < 80

4 (12.5%)

1 (10.0%)

1 (9.1%)

2 (18.2%)

.779

 ≥ 80

28 (87.5%)

9 (90.0%)

10 (90.9%)

9 (81.8%)

Donor type, n (%)

Matched sibling donor

10 (31.3%)

2 (20.0%)

3 (27.3%)

5 (45.5%)

.637

Matched unrelated donor

17 (53.1%)

7 (70.0%)

5 (45.5%)

5 (45.5%)

Mismatched unrelated donor

4 (12.5%)

1 (10.0%)

2 (18.2%)

1 (9.1%)

Haploidentical, mismatched related donor

1 (3.1%)

0 (-)

1 (9.1%)

0 (–)

Stem cell source, n (%)

Peripheral blood

30 (93.8%)

8 (80.0%)

11 (100%)

11 (100%)

.320

Bone marrow

1 (3.1%)

1 (10.0%)

0 (–)

0 (–)

Cord blood

1 (3.1%)

1 (10.0%)

0 (–)

0 (–)

Conditioning regimen, n (%)

Myeloablative (MAC)

23 (71.9%)

8 (80.0%)

10 (90.9%)

5 (45.5%)

.047

Reduced intensity (RIC)

9 (28.1%)

2 (20.0%)

1 (9.1%)

6 (54.5%)

Chemotherapeutic regimen, n (%)

8 Gy TBI/CY2/Fludarabine

15 (46.9%)

7 (70.0%)

5 (45.5%)

3 (27.3%)

.090

FLAMSA-RIC/CY2/4 Gy TBI

9 (28.1%)

2 (20.0%)

1 (9.1%)

6 (54.5%)

12 Gy TBI/CY2

5 (15.6%)

0 (–)

3 (27.3%)

2 (18.2%)

8 Gy TBI/Fludarabine

3 (9.4%)

1 (10.0%)

2 (18.2%)

0 (–)

GvHD-prophylaxis, n (%)

Cyclosporine/MTX

26 (81.2%)

9 (90.0%)

10 (90.9%)

7 (63.6%)

.322

Cyclosporine/Mycophenolate mofetil

4 (12.5%)

1 (10.0%)

0 (–)

3 (27.3%)

Post-transplantation Cyclophosphamide/tacrolimus/Mycophenolate mofetil

2 (6.3%)

0 (–)

1 (9.1%)

1 (9.1%)

Anti-Thymocyte Globulin (ATG), n (%)

Yes

23 (71.9%)

9 (90.0%)

9 (81.8%)

5 (45.5%)

.051

No

9 (28.1%)

1 (10.0%)

2 (18.2%)

6 (54.5%)

Donor-recipient cytomegalic-virus-status, n (%)

Negative/negative

16 (50.0%)

5 (50.0%)

8 (72.7%)

3 (27.3%)

.143

Negative/positive

6 (18.8%)

1 (10.0%)

0 (-)

5 (45.5%)

Positive/positive

6 (18.8%)

2 (20.0%)

2 (18.2%)

2 (18.2%)

Positive/negative

4 (12.5%)

2 (20.0%)

1 (9.1%)

1 (9.1%)

Female donor to male recipient, n (%)

Yes

5 (15.6%)

1 (10.0%)

2 (18.2%)

2 (18.2%)

.840

No

27 (84.4%)

9 (90.0%)

9 (81.8%)

9 (81.8%)

Grade II–IV acute GvHD, n (%)

Yes

12 (37.5%)

4 (40.0%)

4 (36.4%)

4 (36.4%)

.981

No

20 (62.5%)

6 (60.0%)

7 (63.6%)

7 (63.6%)

Acute GvHD grade (n = 12)

Grade II

9 (75.0%)

3 (75.0%)

3 (75.0%)

3 (75.0%)

.558

Grade III

2 (16.7%)

1 (25.0%)

0 (–)

1 (25.0%)

Grade IV

1 (8.3%)

0 (–)

1 (25.0%)

0 (–)

Survival in CR/relapse, n (%)

Survival in CR

29 (90.6%)

10 (100%)

9 (81.8%)

10 (90.9%)

.361

Relapse*

3 (9.4%)

0 (-)

2 (18.2%)¶

1 (9.1%) §

  1. Never cGvHD (chronic Graft-versus-Host Disease): never having cGvHD; Resolved cGvHD: all signs of clinically activity of cGvHD have disappeared, past history of cGvHD, no use of immunosuppression; Active cGvHD: physician reported inflammatory manifestations of cGvHD
  2. TBI 8 Gy/Cy2/Fludarabine: 8 Gy TBI (four 2 Gy doses on two consecutive days), Cyclophosphamide 2 × 60 mg/kg on two consecutive days, Fludarabine 3 × 30 mg/m2 on three consecutive days
  3. FLAMSA-RIC/TBI 4 Gy/Cy2: FLAMSA regimen (d -12 to d -9): Fludarabine 4 × 30 mg/m2, HD-Ara-C 4 × 2000 mg/m2, Amsacrine 4 × 100 mg/m2. Reduced intensity conditioning (RIC)-regimen after 3 days of rest: 4 Gy TBI on d-5 (two 2 Gy doses), Cyclophosphamide (2 × 40 mg/kg for MRD or 2 × 60 mg/kg for MUD, MMRD or MMUD) on d -4 to d -3 , Antithymocyte globulin 10 mg/kg for MRD or 20 mg/kg for MUD, MMRD, MMUD from d-4 to d-2, prophylactic donor lymphocyte infusions at day + 120 or 30 days after discontinuation of immunosuppression: 1–5 × 106 CD3+ cells/kg
  4. TBI 12 Gy/Cy2: 12 Gy TBI (Six 2 Gy doses on three consecutive days, d -7 to d -5), Cyclophosphamide 2 × 60 mg/kg on 2 consecutive days (d -4 to d -3)
  5. TBI 8 Gy/Fludarabine: 8 Gy TBI (four 2 Gy doses on 2 consecutive days, d-5 and d-4), Fludarabine 4 × 30 mg/m2 (d -5 to d -2)
  6. *At time of the evaluation: All patients with relapse in history were in complete remission of the initial diagnosed AML after donor lymphocyte infusions (n = 2 ¶) and therapy with azacitidine (n = 1 §) for a median time of 43.8 months (IQR 34.0, 98.6 months)
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us